READ. SCROLL. LISTEN.

Unbiased headlines. Facts, not spin.

Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.

← Back to headlines

Annovis Says FDA Agreed to Pool Alzheimer's and Parkinson's Safety Data for Buntanetap Application

Annovis Says FDA Agreed to Pool Alzheimer's and Parkinson's Safety Data for Buntanetap Application
Annovis Bio announced today, Nov. 20, that the FDA agreed to its plan for combining safety data from its Alzheimer's and Parkinson's studies of buntanetap. The agreement covers analysis method only, not whether the pill works. The NDA will not be filed until the DUET-AD Alzheimer's trial reads out.

Annovis Bio (NYSE: ANVS) said today, Nov. 20, that the U.S. Food and Drug Administration has agreed to its plan for building the safety section of a future New Drug Application for buntanetap, its once-daily investigational pill for Alzheimer's and Parkinson's disease.

The agreement is about method. It is not an approval, and it says nothing about efficacy.

What the FDA agreed to, per the company

The plan covers an Integrated Summary of Safety, the part of an NDA that evaluates a drug's safety across all of its clinical trials. Annovis proposed pooling safety data from its Alzheimer's and Parkinson's programs and integrating it at the level of standardized analysis datasets.

The company gave three reasons the two diseases can be combined: a common mechanism of action, comparable pharmacokinetics, and similar safety profiles in both conditions.

Annovis said it submitted a draft of its data presentation, integration and calculation methods. The FDA agreed with the dataset-level approach and made recommendations on the statistical methods. Annovis said it will fold those into a final statistical plan and file an updated Study Data Standardization Plan.

The company has not said what the FDA's statistical recommendations were. Its release also names no meeting type or date and does not include FDA correspondence. The account of the FDA's position comes from Annovis.

The studies behind the pool

The pooled analysis will draw on three randomized, double-blind, placebo-controlled studies and one open-label extension.

  • NCT05357989: early Parkinson's, Phase 3, placebo-controlled, completed.
  • NCT05686044: mild to moderate Alzheimer's, Phase 2/3, placebo-controlled, completed.
  • NCT06709014 (DUET-AD): early Alzheimer's, Phase 3, placebo-controlled, still active.
  • An open-label extension in Parkinson's, which Annovis says is also ongoing.

Annovis expects more than 1,600 participants to have received buntanetap across the pooled studies by the DUET-AD six-month data readout.

This is not a sudden shift. In February, CEO Maria Maccecchini said the FDA had indicated it may consider accepting combined safety data in a future NDA. Today's announcement says the agency has now agreed to the plan for doing it.

What it does not settle

Maccecchini framed the deal as a practical advantage. "An NDA has to show not only that a drug works, but that it is safe in a large population treated over a long period," she said. "It also means we can build the safety package now, while DUET-AD and OLE PD are still ongoing."

The company itself draws the line. Annovis said the FDA's agreement "does not constitute approval of buntanetap and does not ensure that the NDA will be accepted for filing or approved." The FDA will decide that after reviewing the full application, including the efficacy and safety results of DUET-AD.

Tech Times, in its own analysis of the announcement, pointed to a limit on the pooled count. Open-label data, where everyone knows they are getting the drug, cannot be compared against placebo. A headline patient total therefore says less about safety than the placebo-controlled portion does. That is Tech Times' reading, not a statement from the FDA or Annovis.

The efficacy question belongs to DUET-AD. Annovis intends to submit the NDA after that trial's data readout. The company has not said when the readout will arrive.

A crowded field for an oral Alzheimer's drug

No oral drug has been approved in the U.S. to slow Alzheimer's. Other companies are chasing that status.

AriBio's AR1001, a low-dose version of a drug sold in South Korea for erectile dysfunction, was tested in a yearlong trial of more than 1,500 people with early Alzheimer's. Its results were presented at the Clinical Trials on Alzheimer's Disease conference by Sharon Sha, a Stanford neurologist who led the trial.

Across the full trial population, the benefit was not statistically significant. In the roughly 40% of participants not taking other dementia drugs, the pill slowed decline by about 31% versus placebo, according to the results presented. AriBio said it plans to ask the FDA whether those results are enough or whether another trial is needed.

That result shows what a pooled safety plan cannot do. A drug can carry a clean-looking safety file and still fail to show it works in the whole population.

Patent position

Separately, Longevity.Technology reported that Annovis has secured a patent on the specific version of buntanetap it uses in patients, with protection running through 2044. Patent protection does not bear on whether the FDA will approve the drug.

What comes next

Annovis has two filings to make: the final ISS statistical plan and the updated Study Data Standardization Plan. Neither has a stated date.

The larger step is the DUET-AD readout, which will show whether buntanetap beats placebo in early Alzheimer's. The NDA depends on that result.

Sources used for this briefing

7 links from 7 independent newsrooms (syndicated copies of the same report count once)

These are the sources it draws on, linked so you can verify.

right
Daily WireOne Of World’s Most Famous Drugs Could Unlock Solution For Alzheimer’s
right
Epoch Times6 Peptides Are No Longer Restricted by the FDA—Here’s What to Know
unknown
GlobeNewswireAnnovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
unknown
MedPathFDA Agrees to Annovis Plan to Pool Alzheimer's and Parkinson's Safety Data for Buntanetap NDA - MedPath Trial
unknown
Longevity TechnologyAnnovis wins patent on Alzheimer’s drug through 2044
unknown
BioSpaceAnnovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
unknown
Tech TimesAlzheimer's Pill Buntanetap: Annovis Says FDA Accepted Pooled Safety Plan; Efficacy Unproven - Tech Times